Although the clinical significance of TMPRSS2-ERG is yet to be proven, presence of the fusion gene is a key genomic event specific for prostate cancer that may be of importance for risk assessment or treatment stratification of prostate cancer patients. The gene discussed is ERG; the disease is prostate carcinoma.